ENOV
Enovis CorporationHealthcare · $1.0B market cap
Verdict
Share price
$17.77
close of Oct 3, 2026
Fair value
$6.09
Sticker Price
Payback Price
$2.43
buy price
ENOV is Overpriced: at $17.77 it trades 192% above its fair value of $6.09. Its buy price (Payback Price) is $2.43, 86% below today's price. Business quality is limited: none of the 5 key numbers clears the 10% bar.
How we valued it
Free Cash Flow Growth. There's too little earnings history to value it on earnings, but it has produced free cash flow consistently, so we value it on cash flow.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ENOV
Get notified when it reaches its buy price of $2.43. Free.
Create a free accountSuperinvestors
2 of the investors we track hold ENOV. In Q2 2026, 1 opened a position. Who we track
Howard Marks
Oaktree Capital Management · as of Q2 2026
$37.8B
39,207,000 shares
Mason Hawkins
Southeastern Asset Management · as of Q2 2026
$916K
44,258 shares
Moves in Q2 2026
New position: Howard Marks
Insider activity
Since Sep 2, 2026: 4 open-market purchases worth $450K. Why purchases matter
Purchases
About Enovis Corporation
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with…
Medical - Devices
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works